𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

✍ Scribed by Branford, S; Rudzki, Z; Harper, A; Grigg, A; Taylor, K; Durrant, S; Arthur, C; Browett, P; Schwarer, A P; Ma, D; Seymour, J F; Bradstock, K; Joske, D; Lynch, K; Gathmann, I; Hughes, T P

Book ID
118676851
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
283 KB
Volume
17
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness of imatinib versus in
Cost-effectiveness of imatinib versus interferon-Ξ± plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 119 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment